Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4415—Pyridoxine, i.e. Vitamin B6
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

• the metadoxme or acceptable derivative thereof may be formulated for immediate release upon administration to the subject.
• the metadoxme or acceptable derivative thereof may be formulated for sustained and/or controlled release, and may optionally be formulated to have both immediate release and sustained and/or controlled release
• an embodiment of the method of the present invention is to administer the therapeutic compound described herein in a sustained release form.
• Any controlled or sustained release method known to those of ordinary skill in the art may be used with the compositions and methods of the invention such as those described in Langer, Science 249(4976): 1527-33 ( 1990).
• Such method comprises administering a sustained-release composition, a suppository, or a coated implantable medical device so that a therapeutically effective dose of the composition of the invention is continuously delivered to a subject of such a method.
• the metadoxine or metadoxine derivative in compositions used by the invention may be formulated for sustained or controlled release over a period of between about 0.5 or 1 or 2 or 3 or 4 hours and about 5, 6, 7, 8, 9, 10, 1 1 or 12 hours. In certain embodiments, the metadoxine or metadoxine derivative in compositions used by the invention may be formulated for sustained or controlled release over a period of between about 5 or 6 or 7 or 8 hours and about 9, 10, 11 or 12 hours.
• the metadoxine or metadoxine derivative in compositions used by the invention may be formulated to release up to 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, 99.5 or 100% of the total metadoxine or metadoxine derivative in about 0.5, 1, 2, 3, 4, 5, 6, 7 or 8 hours.
• metadoxine or metadoxine derivatives formulations of the present invention may be administered in a sufficient amount to produce a reasonable benefit/risk ratio applicable to a selected treatment, as may be determined by the skilled artisan.
• salt adducf is meant to encompass a salt product of a direct addition of two or more distinct ions, wherein the overall charge of the salt adduct is zero.
• the salt adduct comprises one positively charged moiety having a single positive charge functional group (i.e., the positively charged moiety is charged with H- 1 net charge) and one negatively charged moiety having a single negative charge functional group (i.e., the negatively charged moiety is charged with -1 net charge).
• the salt adduct comprises a positively charged moiety charged with +n net charge (originating from one or more positively charged functional groups, which may be the same or different), and a negatively charge moiety having -n (originating from one or more negatively charged functional groups, which may be the same or different) net charge, wherein n is an integer which may be equal to 1 , 2, 3, 4, 5 or 6.
• the successive alleys test effectively measured anxiety (latency to enter the Alley 1 ) and hyperactivity (Alleys 2 to 4). Progression from Alley 1 through the successive Alleys 2, 3, and 4 was associated with exposure to an increasingly brightly colored environment with increasingly lower wails and narrower, more exposed open arms. Time spent on, and entries into, the open arms indicated anxiety; conversely, increasing time spent in more open arms reflected hyperactivity. These factors allowed for a sensitive test bracketing a range of anxiety-like behaviors together with hyperactivity.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Urology & Nephrology (AREA)
• Molecular Biology (AREA)
• Hematology (AREA)
• Food Science & Technology (AREA)
• Microbiology (AREA)
• Cell Biology (AREA)
• Biotechnology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Plant Substances (AREA)
• Steroid Compounds (AREA)

Priority Applications (11)

Applications Claiming Priority (6)

Publications (2)

Family

ID=52629036

Family Applications (2)

Family Applications After (1)

Country Status (12)

Cited By (1)

Families Citing this family (8)

Citations (2)

Family Cites Families (2)

• 2014
  • 2014-09-05 TW TW103130856A patent/TW201605443A/zh unknown
  • 2014-09-05 TW TW103130859A patent/TW201606304A/zh unknown
  • 2014-09-09 AU AU2014315026A patent/AU2014315026A1/en not_active Abandoned
  • 2014-09-09 MX MX2016003002A patent/MX2016003002A/es unknown
  • 2014-09-09 WO PCT/IB2014/002398 patent/WO2015033224A2/en not_active Ceased
  • 2014-09-09 EA EA201690559A patent/EA201690559A1/ru unknown
  • 2014-09-09 WO PCT/US2014/054816 patent/WO2015035402A1/en not_active Ceased
  • 2014-09-09 CA CA2923421A patent/CA2923421A1/en not_active Abandoned
  • 2014-09-09 KR KR1020167009042A patent/KR20160086818A/ko not_active Withdrawn
  • 2014-09-09 CA CA2922901A patent/CA2922901A1/en not_active Abandoned
  • 2014-09-09 KR KR1020167009040A patent/KR20160078956A/ko not_active Withdrawn
  • 2014-09-09 EP EP14830858.8A patent/EP3043792A2/en not_active Withdrawn
  • 2014-09-09 SG SG11201601830PA patent/SG11201601830PA/en unknown
  • 2014-09-09 JP JP2016539645A patent/JP2016530291A/ja active Pending
  • 2014-09-09 EA EA201690557A patent/EA201690557A1/ru unknown
  • 2014-09-09 CN CN201480060722.4A patent/CN105917225A/zh active Pending
  • 2014-09-09 AU AU2014316779A patent/AU2014316779A1/en not_active Abandoned
  • 2014-09-09 CN CN201480049671.5A patent/CN105517546A/zh active Pending
  • 2014-09-09 JP JP2016540930A patent/JP2016530536A/ja active Pending
  • 2014-09-09 MX MX2016003006A patent/MX2016003006A/es unknown
  • 2014-09-09 SG SG11201601605YA patent/SG11201601605YA/en unknown
  • 2014-09-09 EP EP14776939.2A patent/EP3044589A1/en not_active Withdrawn
• 2016
  • 2016-02-29 IL IL244343A patent/IL244343A0/en unknown
  • 2016-03-06 IL IL244453A patent/IL244453A0/en unknown

Patent Citations (2)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events